Klaus Schollmeier

Klaus is an advisor to the Pharma/Biotech industry and member of the board/chairman of several Biotech companies including Anergis Pharma (Switzerland), Affiris Pharma (Austria) and Eternygen (Germany). He also advises and mentors a number of start-up companies in Europe as entrepreneur in residence and business angel. Klaus was Chief Executive Officer of SuppreMol (Germany) from 2013 until 2015, when the company was sold to Baxter. Prior to that, he served as CEO of Santhera (Switzerland), from 2004 to 2011 and chairman of the board of Santhera until 2013. Klaus joined Graffinity Pharmaceuticals AG (Germany) as CEO in 2003 and merged the company with MyoContract AG (Switzerland) in 2004 to form Santhera.

Before joining the biotechnology industry in 2003, he served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Prior to that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Ludwigshafen, Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, USA (from 1989 to 1993). His business functions included general manager of BASF Pharma Netherlands from 1996 to 1998 and vice president and general manager for Western Europe thereafter. From 1994 to 1995, he led BASF’s acquisition and integration of Boots Pharmaceuticals.